Centrum is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 930 in its research report dated May 16, 2018.
Motilal Oswal is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 865 in its research report dated May 15, 2018.
KR Choksey recommended hold rating on Lupin with a target price of Rs 785 in its research report dated May 17, 2018.
India’s second-largest drug maker on Tuesday posted a massive net loss of Rs 783.5 crore in the fourth quarter ended March due to a one-time impairment provision on certain made on certain intangible assets related to Gavis acquisition in US.
The company reported a net profit of Rs 383.6 crore in the period previous year ago. The sales fell 2.8 percent to Rs 4179 crore.
A Reuters poll of equity analysts estimated the net profit to rise to Rs 323.8 crore.
Nagpur facility is the company's latest facility and manufactures oral solid products.
In a BSE filing, Lupin "announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations".
Corcal Bone and Beauty has been introduced under the company’s consumer healthcare division, Lupin Ltd said in a statement.
Lupin said the filing also opens up other key markets like Europe, Canada, Australia, the Middle East, South East Asia and Latin America for this product within the next 12 to 18 months
The company has received final approval from the US Food and Drug Administration (USFDA) for its product which is a generic version of Fougera Pharmaceuticals Inc's Temovate ointment, Lupin Ltd said in a statement.
The market breadth was in favour of the advances with 954 stocks advancing while 724 declined and 378 remained unchanged. On the other hand, in the BSE, 1279 stocks advanced and 1140 declined and 107 remained unchanged.
Net Sales are expected to decrease by 3 percent Y-o-Y (up 3.5 percent Q-o-Q) to Rs. 4,037.9 crore, according to KR Choksey.
Tetrabenazine tablets is a generic version of Valeant Pharmaceuticals North America, LLC's Xenazine tablets, 12.5 mg and 25 mg.
Net Sales are expected to decrease by 10.6 percent Y-o-Y (down 4.4 percent Q-o-Q) to Rs. 3,800 crore, according to HDFC Securities.
Net Sales are expected to decrease by 8.4 percent Y-o-Y (down 2 percent Q-o-Q) to Rs. 3,895.1 crore, according to Edelweiss.
Pharma major Lupin today said the UK health regulator has completed inspection of its Goa facility without making any critical observations.
The market breadth was in favour of the advances with 1432 stocks advancing while 306 declined and 314 remained unchanged. On the other hand, in the BSE, 1997 stocks advanced and 546 declined and 130 remained unchanged.
"Following the review, Health Canada has maintained the compliant rating for unit 2 at Pithampur (Indore) and has issued a revised 'Establishment License'," Lupin said in a BSE filing.
Lupin's product is a generic version of Galderma Laboratories LP's Clobex, which is indicated for treatment of moderate to severe plaque psoriasis.
The company has launched the product in the strength of 25 mg after approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
The market breadth was in favour of the declines with 706 stocks advancing while 902 declined and 407 remained unchanged. On the other hand, in the BSE, 984 stocks advanced and 1126 declined and 135 remained unchanged.
Drug major Lupin today said it has received approval from the US health regulator to market Desoximetasone Topical spray, used for treatment of plaque psoriasis, in the American market.
The market breadth was in favour of the declines with 428 stocks advancing while 1215 declined and 367 remained unchanged. On the other hand, in the BSE, 645 stocks advanced and 1542 declined and 94 remained unchanged.
Mitessh Thakkar of miteshthacker.com recommends buying Bharat Electronics, Tata Motors, Lupin and L&T Finance Holdings.